Responsibility

November 18, 2025 Alnylam Challengers: Empowering Frontline Care for Underserved Communities in Boston We are investing $2 million to advance the essential work of Boston’s frontline Care Navigators through Alnylam Challengers, our Read More ›
August 11, 2025 Everest and Everything In Between: A Journey Back to Nepal One Alnylam employee's personal and spiritual journey home to Nepal and Everest to raise money for cancer research. Read More ›
July 13, 2025 Supporting Newcomer Entrepreneurs - Forward·Inc’s Challengers Pitch Competition Alnylam recently sponsored Forward·Inc’s Challengers Pitch Competition, as part of our ongoing Alnylam Challengers social impact initiative. Read More ›
May 20, 2025 Alnylam Publishes 2024 Corporate Responsibility Report We've published our 2024 Corporate Responsibility Report detailing our efforts in our pillars: Patients, Science, Employees, Communities, Planet, and Governance Read More ›
February 3, 2025 Alnylam Named a Newsweek Most Responsible Company for 2025 Alnylam has been named one of Newsweek's America's Most Responsible Companies for 2025, our third year in a row. Read More ›
January 9, 2025 Supporting Refugees in Europe: Alnylam Challengers and the Path to Empowerment Arun Skaria, Alnylam's Head of DEI and Corporate Responsibility provides an update on Alnylam's efforts to support refugees in Europe Read More ›
August 15, 2024 Alnylam Named a Humankind 100 Company for the 3rd Year in a Row Alnylam has been named to the HumanKind 100 list for the 2nd year in a row and we’re pleased to have moved up in the rankings from #97 in 2022 to #76 in 2023. Read More ›
May 7, 2024 Alnylam Publishes 2023 Corporate Responsibility Report Alnylam's 2023 Corporate Responsibility Report details our corporate responsibility and ESG efforts and progress. Read More ›
April 25, 2024 Our Commitment to Patients Means Never Stop Evolving - Our Patient Access Philosophy Tolga Tanguler, Alnylam's Chief Commercial Officer discusses Alnylam's Patient Access Philosophy and approach to access Read More ›
February 29, 2024 Alnylam Named to Human Rights Campaign’s Corporate Equality Index Alnylam has achieved a score of 90 out of 100 on the Human Rights Campaign's (HRC) 2023-2024 Corporate Equality Index (CEI) based on our US policies, practices, Read More ›

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site